Angiotensin II-induced activation of central AT1 receptors exerts endocannabinoid-mediated gastroprotective effect in rats. by Gyires, Klára et al.
                             Elsevier Editorial System(tm) for Molecular and Cellular Endocrinology 
                                  Manuscript Draft 
 
 
Manuscript Number: MCE-D-12-00534R1 
 
Title: Angiotensin II-induced activation of central AT1 receptors exerts endocannabinoid-mediated 
gastroprotective effect in rats  
 
Article Type: Research Paper 
 
Keywords: angiotensin II; endocannabinoids; gastroprotection; rat; CB1 KO mice 
 
Corresponding Author: Prof. Klára Gyires, M.D., Ph.D 
 
Corresponding Author's Institution: Semmelweis University 
 
First Author: Klára Gyires, M.D., Ph.D 
 
Order of Authors: Klára Gyires, M.D., Ph.D; András Z Rónai; Zoltán S Zádori; Viktória E Tóth; József 
Németh; Mária Szekeres; László Hunyady 
 
Abstract: The aim of the present study was to analyze whether angiotensin II via the endocannabinoid 
system can induce gastric mucosal protection, since transactivation of cannabinoid CB1 receptors by 
angiotensin AT1 receptor in CHO cells was described. Experimental ulcer was induced by acidified 
ethanol given orally in male Wistar rats, CB1(+/+) wild type and CB1(-/-) knock out mice. The 
compounds were administered intracerebroventricularly. It was found, that 1./ Angiotensin II 
inhibited the ethanol-induced gastric lesions (11.9-191 pmol); the effect of angiotensin II (191 pmol) 
was inhibited by the CB1 receptor inverse agonist AM 251 (1.8 nmol) and the inhibitor of 
diacylglycerol lipase (DAGL), tetrahydrolipstatin (0.2 nmol). 2./ Angiotensin II exerted 
gastroprotection in wild type, but not in CB1(-/-) mice. 3./ The gastroprotective effect of angiotensin II 
(191 pmol) was reduced by atropine (1 mg/kg i.v.) and bilateral cervical vagotomy. In conclusion, 
stimulation of central angiotensin AT1 receptors via activation of cannabinoid CB1 receptors induces 
gastroprotection in a DAGL-dependent and vagus-mediated mechanism. 
 
 
 
 
Angiotensin II-induced activation of central AT1 receptors exerts endocannabinoid-mediated 
gastroprotective effect in rats 
 
Klára Gyires
a
*, András Z. Rónai
a†
, Zoltán S. Zádori
a
, Viktória E. Tóth
a
, József Németh
b
, 
Mária Szekeres
c
, László Hunyady
c
 
 
a
Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis 
University, Nagyvárad tér 4., 1089. Budapest, Hungary, 
b
Department of Pharmacology and Pharmacotherapy, University of Debrecen, Nagyerdei krt. 
98., 4032. Debrecen, Hungary, 
cDepartment of Physiology, Faculty of Medicine, Semmelweis University, Tűzoltó u. 37-47., 
1094. Budapest, Hungary 
† 
For the memory of our co-author, András Z. Rónai, an outstanding peptide pharmacologist 
 
 
 
 
*: Corresponding author: Klára Gyires, Department of Pharmacology and Pharmacotherapy, 
Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., 1089. Budapest, Hungary 
Phone: 36-1-210-4416 
Fax: 36-1-210-4412 
email: gyirkla@net.sote.hu 
*Manuscript
Click here to view linked References
Abstract 
The aim of the present study was to analyze whether angiotensin II via the endocannabinoid 
system can induce gastric mucosal protection, since transactivation of cannabinoid CB1 
receptors by angiotensin AT1 receptor in CHO cells was described. Experimental ulcer was 
induced by acidified ethanol given orally in male Wistar rats, CB1(+/+) wild type and CB1(-/-) 
knock out mice. The compounds were administered intracerebroventricularly. It was found, 
that 1./ Angiotensin II inhibited the ethanol-induced gastric lesions (11.9-191 pmol); the effect 
of angiotensin II (191 pmol) was inhibited by the CB1 receptor inverse agonist AM 251 (1.8 
nmol) and the inhibitor of diacylglycerol lipase (DAGL), tetrahydrolipstatin (0.2 nmol). 2./ 
Angiotensin II exerted gastroprotection in wild type, but not in CB1(-/-) mice. 3./ The 
gastroprotective effect of angiotensin II (191 pmol) was reduced by atropine (1 mg/kg i.v.) 
and bilateral cervical vagotomy. In conclusion, stimulation of central angiotensin AT1 
receptors via activation of cannabinoid CB1 receptors induces gastroprotection in a DAGL-
dependent and vagus-mediated mechanism. 
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Abbreviations 
Ang II: Angiotensin II; AT1 receptor: angiotensin AT1 receptor; 2-AG: 2-
arachidonoylglycerol; CHO: Chinese hamster ovary; CGRP: calcitonin gene-related peptide; 
DAG: diacylglycerol; DAG lipase: diacylglycerol lipase; THL: tetrahydrolipstatin 
1. Introduction 
 
Cannabinoid receptors are a class of cell membrane receptors under the G protein-
coupled receptor (GPCR) superfamily (Matsuda et al., 1990). To date, two cannabinoid 
receptors have been identified by molecular cloning, CB1 and CB2 receptors (Howlett et al., 
2002; Matsuda et al., 1990; Munro et al., 1993), however the existence of additional CB 
receptors have also been proposed (Brown, 2007; Pacher et al., 2005; Ryberg et al., 2007). 
CB1 receptors are expressed by central and peripheral neurons, while CB2 receptors 
are mainly expressed by immune cells. The major and best characterized endocannabinoids 
are arachidonylethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG). The 
endocannabinoids are synthesized on demand by neurons and brain tissue in response to 
increased intracellular calcium concentrations or during calcium signal generation. 
Anandamide is a partial or full agonist of CB1 receptors, depending on the tissue and 
biological response measured. Although it also binds to CB2 receptors, it has very low 
efficacy and may act as an antagonist (Gonsiorek et al., 2000). 2-AG acts as a full agonist and 
is the true natural ligand for both the CB1 and the CB2 receptors (Sugiura et al., 2006). 
Anandamide is produced from the membrane phospholipid N-arachidonoyl by a 
phospholipase C dependent process, while 2-AG is generated by diacylglycerol lipases 
(DAGLs) from diacylglycerol (DAG), which is produced during the signaling of Ca
2+
-
mobilizing hormones, such as angiotensin II (Ang II) (Gyombolai et al., 2012). 
Mounting evidence suggest that cannabinoid receptors and their ligands are involved 
in numerous physiological and pathophysiological processes. In the central nervous system 
endocannabinoids can be produced postsynaptically, and act on presynaptic cannabinoid 
receptors as retrograde transmitters after they are translocated across the plasma membrane 
(Freund et al., 2003). CB1 receptors located presynaptically in several brain regions act as 
inhibitory retrograde signaling messengers at glutamatergic and GABAergic synapses, 
modulating the release of several neurotransmitters (Marsicano and Lutz, 1999; Piomelli, 
2003). Thus, the endocannabinoid system, through its neuromodulating activity, could be 
involved in several physiological functions, including memory processing, pain perception, 
locomotion and inflammation; additionally, its dysregulation could underlie several 
pathological conditions known to accompanying psychiatric disorders (Di Marzo, 2008). In 
human therapy CB1 receptor agonists (e.g. dronabinol) are already used against 
chemotherapy-induced nausea and vomiting, whereas CB1 receptor antagonist rimonabant 
was introduced in the therapy of obesity (Pacher et al., 2006), however, it was withdrawn 
from the market due to increased risk of suicide and depression (Steinberg and Cannon, 
2007). Nevertheless, specific targeting of peripheral CB1 receptors (Kunos et al., 2009) and/or 
identification of the population, which is genetically resistant to the central side effects of 
rimonabant is still under consideration (Lazary et al., 2011). Furthermore, modulating CB1 
receptor activity has therapeutic potential in a wide range of pathological conditions including 
mood and anxiety disorders, movement disorders, neuropathic pain, and multiple sclerosis, as 
well as cancer, cardiovascular diseases, obesity/metabolic syndrome and musculoskeletal 
disorders (Pacher et al., 2006). 
Increasing number of evidence suggest that CB1 receptors may play a role in the 
modulation of gastrointestinal functions. Cannabinoids were shown to inhibit gastrointestinal 
motility (Izzo et al., 1999; Krowicki et al., 1999), gastric acid secretion (Adami et al., 2002) 
and development of gastric mucosal lesions both in acid-dependent (Germano et al., 2001; 
Rutkowska and Fereniec-Goltbiewska, 2006) and acid-independent ulcer models (Shujaa et 
al., 2009). Accordingly, CB1 receptors were identified in neurons of the enteric nervous 
system and in sensory terminals of vagal and spinal neurons, moreover, CB1 receptors are also 
identified in the dorsal vagal complex: in the nucleus of the solitary tract (NTS) 
(Partosoedarso et al., 2003), in the dorsal motor nucleus of vagus (DMNV) (Mackie, 2005) 
and prominently, in the area postrema (Mackie, 2005). 
Paracrine transactivation of CB1 receptors by co-expressed type 1 angiotensin 
receptors (AT1) in Chinese hamster ovary (CHO) cells was observed recently (Turu et al., 
2007). AT1 receptor is a Gq-protein-coupled receptor. Activation of Gq/11 protein-coupled 
receptors results in activation of phospholipase C, which produces inositol-trisphosphate and 
diacylglycerol (DAG) from phosphatidylinositol (4,5)-bisphosphate. From DAG 2-AG is 
generated by diacylglycerol lipases (DAGLs). Accordingly, inhibition of DAGL in CHO cells 
interfered with the activation of CB1 receptors (Turu et al., 2007). The inhibitory effect of 
DAGL-inhibitor on these processes suggests that these actions are mediated mainly by 2-AG 
(Bisogno et al., 2005; Makara et al., 2005; Turu et al., 2009). 
Since our recent findings showed that anandamide and synthetic cannabinoid 
analogues given centrally induced gastric mucosal protection by CB1 receptor-mediated 
mechanism in the rat (Shujaa et al., 2009), the present study was designed to examine whether 
Ang II injected centrally can induce gastric mucosal defense in the rat and mouse via 
activation of the endocannabinoid system. 
Here we show, that i.c.v. injection of both anandamide, 2-AG and Ang II induced 
gastric mucosal protection in the rat. The protective action of Ang II was likely to be mediated 
via activation of AT1 and CB1 receptors. The protective effect was decreased by 
tetrahydrolipstatin, an inhibitor of DAGL, the principle enzyme responsible for synthesis of 2-
AG. Moreover, Ang II induced gastroprotective effect also in wild type mice, however, it 
failed to exert mucosal protective effect in CB1 receptor deficient mice. Consequently, these 
data are the first in vivo evidence on the interaction between central AT1 receptors and the 
endocannabinoid system in a DAGL-dependent mechanism. 
 
2. Materials and methods 
 
2.1. Animals 
Experiments were carried out on male Wistar rats weighing 150-170 g received from 
the breeding colony of Semmelweis University and on CB1 receptor knockout (-/-, CB1R KO) 
and wild type (+/+, WT) C57BL/6J mice (21-25 g), kindly provided by Professor Andreas 
Zimmer, University of Bonn (Zimmer et al., 1999). 
The animals were kept in a 12-hour light/dark cycle and under condition of controlled 
temperature. They were maintained on standard rat laboratory chow and tap water ad libitum. 
All efforts were made to minimize animal suffering and to reduce the number of 
animals used in the experiments. All procedures conformed to the European Convention for 
the protection of vertebrate animals used for experimental and other scientific purposes. The 
study was approved by the Animal Ethics Committee of Semmelweis University, Budapest 
(permission number: 22.1/606/001/2010). 
 
2.2. Experimental procedures 
Gastric mucosal damage induced by acidified ethanol 
After 24 h food deprivation 0.5 or 0.2 ml acidified ethanol (98 ml absolute ethanol + 2 
ml concentrated HCl) was given orally to the rats and mice, respectively. 60 min later the 
animals were sacrificed, the stomachs were excised, opened along the greater curvature, 
rinsed with saline and examined for lesions. Total number of mucosal lesions was assessed in 
blinded manner by calculating the ulcer index based on a 0-4 scoring system described 
previously (Gyires, 1990). The ulcer index was calculated as the total number of lesions 
multiplied by the respective severity factor. 
 
The percentual inhibition of mucosal damage was calculated as follows: 
 
           ulcer index in treated group 
100 -              x 100  
 ulcer index in control group 
Drugs were injected intracerebroventricularly (i.c.v.) to the lateral ventricle as 
described previously (Gyires et al., 2000) in a volume of 10 μl and 5 μl for rats and mice, 
respectively, 10 min before the ethanol challenge. To avoid a rapid increase of 
intracerebroventricular pressure the syringe was put into a special apparatus which allowed to 
inject the volume during optional (1 min) period. The antagonists (the CB1 receptor inverse 
agonist AM 251, the AT1 receptor antagonist candesartan and the DAGL inhibitor THL) were 
injected together with the agonists. 
The doses of the antagonists were selected partly on the basis of our preliminary 
experiments, partly on the basis of the literature (for AM 251: Bakkali-Kassemi et al., 2011; 
for candesartan: Fujisawa et al., 2011; Nishimura et al., 1998; for tetrahydrolipstatin: Gregg et 
al., 2012). The doses of agonists were selected on the basis of dose-response curves: 115 and 
26.4 nmol for anandamide and 2-AG, respectively, and 191 pmol for Ang II. Atropine was 
given intravenously (i.v.) 15 min before the i.c.v. injection of Ang II. 
Bilateral cervical vagotomy 
Under pentobarbital anaesthesia (35 mg/kg intravenously), the cervical section of 
vagal nerves was exposed and bilateral cervical vagotomy was performed. Vagotomy slowed 
the respiration phase and enlarged the magnitude of respiration. Sham operated control rats 
had their vagus similarly exposed but the vagal trunks were not sectioned. The incisions were 
closed and all animals were allowed 3 hours recovery from operation. 
Determination of gastric mucosal CGRP level 
For determination of gastric mucosal level of calcitonin gene-related peptide (CGRP) 
the rats were anesthetized with ether, the stomachs were removed and gastric mucosa was 
separated on a cooled plate. It was weighed and put in 1 ml cold distilled water, sonicated and 
stored at -80 ºC till the determination. 
CGRP concentration was determined by radioimmunoassay (RIA) described 
previously (Németh et al., 1998). For the specific RIA the antiserum (C1012) was raised in 
rabbit immunized with synthetic peptide conjugated to thyroglobulin by glutaraldehyde. The 
RIA tracer was mono-
125
l-labelled peptide prepared by Németh et al. (2002). Synthetic 
peptide was used as RIA standard ranging from 0 to 100 fmol/ml. The detection limit of the 
assay was 0.2 fmol/ml. This technique has proved to be specific, sensitive and valid for the 
measurement of neuropeptides in pharmacological research. CGRP concentration was 
calculated as the measured amount of peptide per wet tissue weight, expressed as fmol/mg. 
 
2.3. Materials 
Arachidonylethanolamide (anandamide), 2-arachidonoylglycerol (2-AG) and angiotensin II 
(Ang II) (human) were ordered from Ascent Scientific Ltd. (Bristol, UK). N-(Piperidin-1-yl)-
5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM 251) 
were purchased from Tocris Bioscience (Bristol, UK),while N-Formyl-L-leucine(1S)-1-
[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl] methyl] dodecyl ester (tetrahydrolipstatin), atropine 
sulphate and pentobarbital sodium were purchased from Sigma Chemical Co. (St. Louis, MO, 
USA). Candesartan was ordered from Toronto Research Chemicals (Toronto, Canada). 
The stock solutions of anandamide (ethanol), 2-AG (acetonitrile) and AM-251 (DMSO) were 
diluted with saline. All the other drugs were dissolved in saline. Animals in the control groups 
received the drug solvents. 
 
2.4. Statistical analysis 
All data are presented as the means ± S.E.M. Statistical analysis of the data was 
evaluated by means of analysis of variance (ANOVA) followed by Newman–Keuls test for 
multiple comparisons. A probability value of less than 0.05 was considered statistically 
significant. 
 
3. Results 
 
3.1. The effect of anandamide and 2-AG on ethanol-induced gastric mucosal damage 
and gastric mucosal level of CGRP. 
 
Both anandamide and 2-AG in the doses of 2.9-115 and 3.3-26.4 nmol i.c.v., 
respectively, inhibited the development of ethanol-induced gastric mucosal lesions in a dose-
dependent manner (Fig. 1), however, at higher dose (52.8 nmol) the protective effect of 2-AG 
was diminished. AM 251 (1.8 nmol i.c.v.), an inverse agonist of the CB1 cannabinoid 
receptor, failed to affect the ethanol-induced gastric mucosal lesions, but reversed the 
gastroprotective effect of both anandamide (115 nmol i.c.v.) and 2-AG (6.6 nmol i.c.v.) 
suggesting the involvement of central CB1 cannabinoid receptors in the mucosal defensive 
processes (Fig. 2). 
The mucosal CGRP content decreased from 1.34 ± 0.1 fmol/mg to 0.25 ± 0.1 fmol/mg 
(p<0.001) values 60 min after oral administration of ethanol. I.c.v. administration of the 
vehicles failed to affect the mucosal CGRP content. Anandamide (58 nmol i.c.v.) and 2-AG 
(26.4 nmol i.c.v.) given 10 min before the ethanol administration restored the ethanol-induced 
decrease of mucosal CGRP level (1.20 ± 0.1 fmol/mg and 1.15 ± 0.1 fmol/mg, respectively) 
(Fig. 3). 
 3.2. The effect of Ang II and its combination with candesartan, AM 251 and THL on 
ethanol-induced gastric mucosal damage in the rat. 
 
Ang II inhibited the ethanol-induced gastric mucosal lesions in a dose-dependent 
manner in the doses of 11.9-191 pmol i.c.v., however at higher dose (956 pmol) the mucosal 
protective effect was diminished (Fig. 4). I.c.v. injection of the AT1 receptor antagonist 
candesartan inhibited the gastroprotective effect of Ang II (191 pmol) in a dose dependent 
manner (5.2 and 31.7 nmol) (Fig. 5A). Moreover, the inverse agonist of CB1 cannabinoid 
receptor, AM 251 (1.8 nmol, Fig. 5B) and the DAGL inhibitor THL (0.2 nmol, Fig. 5C) also 
interfered with the gastroprotective effect of AngII (191 pmol). None of the antagonists 
affected the ethanol-induced gastric mucosal lesions in a significant manner per se. 
 
3.3. The effect of Ang II on cannabinoid CB1(+/+) wild type and CB1(-/-) knock out mice. 
 
 Ang II (191 pmol i.c.v.) inhibited the ethanol-induced mucosal lesions in wild type 
mice (ulcer indices: 107.8 ± 7.3 vs. 29.2 ± 4.7). However, Ang II in the same dose failed to 
elicit mucosal protective effect in CB1 receptor deficient mice (ulcer indices: 97.8 ±2.4 vs. 
85.7 ± 7.9, Fig. 6). Fig. 7 illustrates representative macroscopic pictures of the protective 
effect of Ang II in wild type and in CB1 receptor deficient mice. 
 
3.4. The effect of bilateral cervical vagotomy and atropine on the gastroprotective action 
of Ang II in the rat. 
 
In sham operated rats Ang II (191 pmol) exerted a highly significant inhibition of 
ethanol-induced mucosal damage. Bilateral cervical vagotomy resulted in a slight, but not 
significant aggravation of gastric mucosal lesions compared to sham operated rats and 
reduced in a significant manner the Ang II-mediated gastric mucosal protective effect (Fig. 
8A). Atropine (1 mg/kg i.v.) failed to affect the ethanol-induced mucosal lesions, however, 
given 15 min before the i.c.v. administration of Ang II reduced in a significant manner the 
mucosal protective effect of Ang II, though did not abolish it (Fig. 8B). 
 
4. Discussion 
 
G protein-coupled receptors mediate the effects of several neurotransmitters and 
neuromodulators on the target cells by stimulating G protein dependent and independent 
intracellular signaling pathways (DeWire et al., 2007; Hunyady and Catt, 2006; Lefkowitz, 
2004). Activation of Gq/11 protein-coupled receptors results in phospholipase C activation, 
which produces inositol-trisphosphate and DAG from phosphatidylinositol (4,5)-
bisphosphate, and DAG can be converted to 2-AG by DAGL (Basavarajappa, 2007; Sugiura 
et al., 2006). 
It was recently shown that activation of the Gq/11-coupled angiotensin AT1 receptor 
by angiotensin II resulted in activation of cannabinoid CB1 receptors via a DAGL-dependent 
mechanism in CHO cells (Turu et al., 2007). Namely, it was observed that inhibition of 
DAGL in these cells led to inhibition of the constitutive activity of CB1 receptors, and similar 
results were obtained in HEK-293 cells (Turu et al., 2007, 2009). The transactivation of 
cannabinoid CB1 receptors by Ang II is supported by the finding that showed an inhibitory 
effect of AM 251, inverse agonist of CB1 receptors, on the hypertensive effect of Ang II 
injected directly into the hypothalamic paraventricular nucleus of anaesthetized rats 
(Gyombolai et al., 2012). Vice versa, AT1 receptor expression may be directly regulated by 
CB1 receptors, namely in cultured vascular smooth muscle cells inhibition of CB1 receptor by 
rimonabant and AM 251 led to down-regulation of AT1 receptor expression (Tiyerili et al., 
2010). 
Cannabinoids are involved in numerous physiological and pathophysiological 
processes, and affect also gastrointestinal functions. For example they inhibit GI transit and 
motility in rats (Landi et al., 2002), decrease the intragastric pressure and the pyloric 
contractility by activating CB1 receptors (Krowicki et al., 1999), tonically inhibit colonic 
propulsion (Pinto et al., 2002) and decrease GI transit in mice (Izzo et al., 2000). CB1 receptor 
agonists decreased the gastric acid secretion induced by pentagastrin given intravenously 
(Adami et al., 2002), but i.c.v. injection of the synthetic non-selective agonist WIN 55,212-2 
was ineffective in preventing the pentagastrin stimulated gastric acid secretion (Adami et al., 
2004). Cannabinoids have been shown to decrease the formation of experimental gastric 
ulcers as well. Tetrahydrocannabinol, for example, reduced mucosal damage induced by 
pylorus ligation (Sofia et al., 1978) and Cannabis sativa was effective against restraint-
induced gastric ulcerations (De Souza et al., 1978). Furthermore, anandamide reduced the 
gastric ulceration induced by water immersion and restraint stress (Dembinski et al., 2006) 
and WIN55,212-2 produced anti-ulcer effect in the cold/restraint stress model (Germano et 
al., 2001). Moreover, the selective CB1 receptor agonist ACEA (arachidonyl-2-
chloroethylamide) significantly reduced gastric ulcer formation induced by aspirin 
(Rutkowska and Fereniec-Goltbiewska, 2006). 
The ulcer models used in the above experiments are gastric acid-dependent models, 
consequently, the inhibition of the mucosal lesions can be due either to inhibition of gastric 
acid secretion, or stimulation of gastric mucosal defense (or both). Moreover, since 
cannabinoids have been given peripherally, no conclusion could be drawn on the site of 
action, whether it is central or peripheral (or both), because cannabinoids are lipophilic 
compounds and easily pass the blood-brain barrier. We showed recently that anandamide and 
synthetic cannabinoids given i.c.v. exerted gastroprotective effect against the acid-
independent ethanol ulcer model. Moreover, the mucosal protective effect of intravenously 
injected methanandamide was reversed by the centrally injected CB1 receptor antagonist SR 
141716A, indicating the role of central CB1 receptors in the gastroprotection (Shujaa et al., 
2009). As our present results indicate, the gastroprotective effect of centrally administered 
anandamide and 2-AG may be due - at least partly - to elevation of CGRP in gastric mucosa, 
which was dramatically decreased following ethanol challenge. There is evidence that CGRP-
containing capsaicin-sensitive primary afferent nerves participate in the control of gastric 
mucosal integrity by inducing mucosal vasodilation and increased mucosal microcirculation 
mediated partly by NO release (Holzer et al., 1990, 1991). 
Since paracrine transactivation of the CB1 receptors by angiotensin AT1 receptors has 
recently been observed (Turu et al., 2009), we aimed to test if activation of central AT1 
receptors by Ang II results in gastric mucosal protection through a cannabinoid-dependent 
mechanism. It was found that Ang II injected i.c.v. induced a dose-dependent inhibiton of 
ethanol-induced mucosal lesions in picomolar dose range. In higher dose range, however, the 
gastroprotective effect was reduced. Similar bell-shaped dose-response curve was observed 
following central administration of clonidine (Gyires et al., 2000), nociceptin (Zádori et al., 
2008) and substance P (Brancati et al., 2013) in the ethanol-ulcer model. Though the precise 
mechanism of the bell shaped dose-response curves has not been known, it might be 
speculated that in high doses the selectivity of the compounds to the receptor responsible for 
the gastroprotective effect is lost and the compound may bind to additional receptors. 
Activation of these receptors may counteract the primary action manifesting in reduced effect. 
Or it also might be raised that administration of higher doses results in formation of 
biologically active metabolites that could diminish the effect of the parent compound. 
The protective effect was reversed by candesartan indicating that the effect was 
mediated by AT1 receptors. AM 251, an inverse agonist of CB1 receptors, also decreased the 
Ang II-induced mucosal protective effect suggesting the AT1 receptor-initiated activation of 
the endocannabinoid system. Moreover, we aimed to clarify, whether a DAGL-dependent 
mechanism plays a role in the effect of Ang II, similarly to that observed in CHO cells. It was 
found that inhibition of DAGL by THL antagonized the gastroprotective effect of Ang II, 
which implies that the mucosal protection induced by Ang II is likely to be mediated by 2-AG. 
A convincing evidence for the role of CB1 receptors in Ang II-induced gastric mucosal 
protection was obtained by the experiment performed in genetically engineered mice: Ang II 
exerted gastric mucosal protective effect in wild type mice, but not in CB1 receptor deficient 
mice. 
Ang II was initially described as a hormone of peripheral origin, the active end product 
of the renin-angiotensin system. The discovery of brain Ang II receptors located in neurons 
inside the blood brain barrier confirmed the existence of an endogenous brain Ang II system. 
Classical actions of Ang II in the brain include the regulation of hormone formation and 
release, the control of sympathoadrenal systems (both centrally and peripherally) the 
regulation of water and sodium intake. However, AT1 receptors are localized not only in areas 
related to the regulation of autonomic and endocrine control, but also in many other areas of 
the brain responsible for emotional, sensory and motor functions. For example central Ang II 
through AT1 receptors may be a specific brain modulatory factor in the control of the reaction 
to stress (Mayorov, 2011; Saavedra et al., 2011). Stress can affect not only the hormonal and 
cardiovascular system, but also the gastric mucosal integrity and can initiate gastric mucosal 
damage. A potent, non-peptide AT1 receptor antagonist with a good penetration to the brain 
given peripherally inhibited the development of stress-induced gastric ulcers (Armando et al., 
2003). Similarly, in spontaneously hypertensive rats 2 weeks treatment with AT1 receptor 
antagonist candesartan (given subcutaneously) resulted in inhibition of stress-induced 
ulcerations, by protection of gastric mucosal blood flow, decreased sympathoadrenal 
activation and prevention of the stress-induced inflammatory response of the gastric mucosa 
(Bregonzio et al, 2003; Saaverda and Benicky, 2007). Moreover, telmisartan and in a lesser 
extent candesartan were shown to inhibit indomethacin- and cold restraint-stress induced 
gastric ulcer formation, gastric acid secretion and the oxidative stress of gastric mucosa, and 
partial peroxisome proliferator-activated receptor gamma agonistic properties were supposed 
to play a role in the anti-ulcer action (Morsy et al., 2009). In addition the central, anti-stress 
effect may also contribute to the gastroprotective effect of the angiotensin II AT1 receptor 
blocking drugs. 
However, data of the literature suggest that not only the blockade but activation of 
central AT1 receptor can also elicit gastric mucosal protection, e.g. microinjection of Ang II 
into the PVN inhibited mucosal injury in gastric ischemia-reperfusion induced ulcer model in 
a dose-dependent manner. The underlying mechanism is the increase of gastric blood flow, 
which effect turned to be mediated by central AT1 receptors (Zhang et al., 2008). Moreover, 
reversal of the elevated mucosal level of NF-kappaB during gastric ischemia-reperfusion by 
Ang II may contribute to the Ang II-induced protection against injury (Zhang et al., 2008). 
Accordingly, also our present findings suggest that activation of central AT1 receptors may 
elicit gastric mucosal protection against an acid independent, ethanol-ulcer model via the 
endocannabinoid system both in rats and mice. 
The precise mechanism and site of centrally initiated gastroprotective action has been 
intensively analyzed. The dorsal vagal complex is likely to have a prominent role in 
conveying the centrally initiated effect to the periphery. It was shown that both vagotomy and 
atropine decreased the gastroprotective effects of centrally injected thyrotropin releasing 
hormone (TRH), adrenomedullin, peptide YY, opioid peptides, clonidine (for reviews see 
Gyires, 2005; Tache 2012), nociceptin, nocistatin and cannabinoids (Shujaa et al., 2009; 
Zádori et al., 2008). Pharmacological and biochemical studies have shown that activation of 
vagal cholinergic pathways stimulates gastric prostaglandin and NO release and the “efferent 
function” of capsaicin sensitive primary afferent fibers containing CGRP (Kato et al., 1994; 
Saperas et al., 1995; Yoneda and Tache, 1993). Also nucleus of the solitary tract (NTS) was 
hypothesized to be involved in centrally initiated gastroprotective effect of clonidine and 
opioid peptides (Gyires et al., 2000). 
As the present results show bilateral cervical vagotomy reduced in a significant 
manner the gastroprotective effect of centrally given Ang II indicating that vagal nerve is 
likely to be involved in conveying the centrally initiated effect to the periphery. Since atropine 
also significantly inhibited (but not abolished) the mucosal protective effect of Ang II, the 
involvement of cholinergic muscarinic receptors in the protective effect is suggested. This 
assumption is supported by the results of Lenkei et al. (1998) who found high AT1 messenger 
RNA expression in the hypothalamic periventricular nucleus, in the paraventricular nucleus, 
in the NTS and in the area postrema. Others found that Ang II receptors have been detected at 
all levels of the vagal sensory and motor system (Diz et al., 2002). The role of the dorsal vagal 
complex in AT1 receptor-mediated actions was suggested by the findings, that microinjections 
of ANG-(1-12) (0.06 mM) into the NTS decreased the mean arterial pressure and heart rate by 
activation of AT1 receptors, and bilateral vagotomy abolished this effect (Chitravanshi and 
Sapru, 2011). Moreover, microinjection of Ang II into the dorsal motor nucleus of vagus 
resulted in increased vagal outflow to the heart and GI tract (Diz et al., 1984). In addition, 
microinjection of low (femtomolar) doses of Ang II into the dorsal medial region of the NTS 
produced a transient fall in blood pressure and heart rate in anesthetized rats (Fow et al., 1994; 
Mosqueda-Garcia et al., 1990; Rettig et al., 1986), however, higher doses evoked pressor 
responses (Casto and Phillips, 1986; Luoh and Chan, 1998; Michelini and Bonagamba, 1990) 
creating a bisphasic dose-response curve. Interestingly, the mucosal protective effect of i.c.v. 
injected Ang II proved to be also biphasic, in low (picomolar) doses it induced a pronounced 
gastroprotective action, however, the effect was decreased when higher doses were given. 
Both AT1-and CB1-receptors were identified in the NTS, in the dorsal motor nucleus 
of vagus and in the paraventricular nuclei (Castelli et al., 2007; Partosoedarso et al., 2003; 
Seagard et al., 2004). On the basis of this findings it may be speculated that AT1 receptor-
induced activation of CB1 receptors might take place in the dorsal vagal complex, however, 
whether there is an overlap in expression of CB1 and AT1 receptors in this brain area remains 
to be clarified. Moreover, since both vagotomy and atropine reduced, but did not abolish the 
protective effect of Ang II, besides vagal nerve additional mechanism - for example the 
sympathetic nervous system - may also play a role in conveying the centrally initiated action 
to the gastric mucosa. 
In summary, here we showed that Ang II exerted gastroprotective effect injected i.c.v., 
via activating the endocannabinoid system, since both CB1 cannabinoid receptor antagonist 
and inhibitor of DAGL (responsible for the synthesis of 2-AG) decreased the effect of Ang II. 
In addition, Ang II induced mucosal protective effect in wild type, but not in CB1 cannabinoid 
receptor deficient mice. The centrally initiated protective effect is likely to be vagal 
dependent. Our results support the hypothesis on the central neuronal control of GI functions, 
which is based on a complex array of interconnecting brain structures and neuro-chemical 
systems and characterised by redundancy seen not only in the manner as certain brain areas 
participate in regulation of GI functions, but also in the extent to which certain 
neurotransmitters, neuropeptides modify these functions. 
However, further studies are needed to clarify several questions. First of all, how Ang 
II can induce activation of endocannabinoid (2-AG) system in vivo. Whether CB1 and AT1 
receptors are co-localized and the transactivation of CB1 receptors by AT1 receptors is valid 
also under in vivo condition and play a role in Ang II - cannabinoid interaction, remains to be 
determined. Or other mechanisms may also be raised: whether Ang II through activation of 
AT1 receptor might increase the synthesis/release of 2-AG. Furthermore, how can it be 
explained that antiulcer effect can be induced both by stimulation (ischemia-reperfusion- and 
ethanol-induced lesions) and inhibition (stress-ulceration, indomethacin-induced lesions) of 
AT1 receptors? What is the role of central and peripheral AT1 receptors in gastric mucosal 
protection/damage? Analysis of these issues may help to clarify the potential role of renin-
angiotensin system in gastric mucosal integrity. 
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Figure captions 
Fig. 1.  
 The inhibitory effect of intracerebroventricularly (i.c.v.) injected anandamide (2.9 - 
115 nmol/rat) and 2-arachidonoylglycerol (2-AG, 3.3 - 52.8 nmol/rat) on gastric mucosal 
injury induced by ethanol. Drugs were injected 10 min before the ethanol challenge. Each 
column represents mean ± S.E.M., the number of animals was 5 per group. *P<0.05; 
***P<0.001 (ANOVA, Newman-Keuls post hoc test, compared with the respective control 
group). 
 
Fig. 2.  
 The effect of AM 251 (1.8 nmol/rat i.c.v.) on the gastroprotective effect of 
anandamide (115 nmol/rat i.c.v., Fig. 2A) and 2-arachidonoylglycerol (2-AG, 6.6 nmol/rat 
i.c.v., Fig. 2B). AM 251 was injected together with the agonists 10 min before the ethanol 
challenge. Each column represents mean ± S.E.M., n=5 per group. **P<0.01; ***P<0.001 
compared with the vehicle-treated group (column 1); 
##
P<0.01; 
###
P<0.001 compared with the 
agonist-treated group (column 2) (ANOVA, Newman-Keuls post hoc test). 
 
Fig. 3.  
The effect of anandamide (58 nmol/rat) and 2-arachidonoylglycerol (2-AG, 26.4 
nmol/rat) on gastric mucosal CGRP content measured 1 h after ethanol administration. Each 
column represents mean ± S.E.M., the number of animals was 5 per group. ***P<0.001 
compared with the control group (column 1); 
##
P<0.01 compared with the vehicle-treated 
group (column 3). 
 
Fig. 4.  
The effect of intracerebroventricularly (i.c.v.) injected angiotensin II (2.9 - 956 
pmol/rat) on gastric mucosal injury induced by ethanol. Angiotensin II was injected 10 min 
before the ethanol challenge. Each column represents mean ± S.E.M., the number of animals 
was 5 per group. **P<0.01; ***P<0.001 (ANOVA, Newman-Keuls post hoc test, compared 
with the respective control group). 
 
Fig. 5.  
 The effect of candesartan (5.2 and 31.7 nmol/rat i.c.v., Fig. 5A), AM 251 (1.8 nmol/rat 
i.c.v., Fig. 5B) and tetrahydrolipstatin (THL, 0.2 nmol/rat i.c.v., Fig. 5C) on the 
gastroprotective effect of angiotensin II (191 pmol/rat i.c.v.). Antagonists were injected 
together with angiotensin II 10 min before the ethanol challenge. Each column represents 
mean ± S.E.M., n=5 per group. **P<0.01; ***P<0.001 compared with the vehicle-treated 
group (column 1); 
#
P<0.05; 
##
P<0.01 compared with the angiotensin II-treated group (column 
2) (ANOVA, Newman-Keuls post hoc test). 
 
Fig. 6.  
 The gastroprotective effect of intracerebroventricularly (i.c.v.) injected angiotensin II 
(191 pmol/rat) on gastric mucosal injury induced by ethanol in wild type (WT) and CB1 
receptor deficient (CB1(-/-)) mice. Angiotensin II was injected 10 min before the ethanol 
challenge. Each column represents mean ± S.E.M., the number of animals was 6 per group. 
***P<0.001 compared with the vehicle-treated wild type mice (column 1); 
###
P<0.001 
compared with angiotensin II-treated wild type mice (column 2) (ANOVA, Newman-Keuls 
post hoc test). 
 
Fig. 7. 
Macroscopic picture of the effect of intracerebroventricularly (i.c.v.) injected 
angiotensin II (191 pmol/rat) on gastric mucosal injury induced by ethanol in wild type and 
CB1 receptor deficient mice. Angiotensin II was injected 10 min before the ethanol challenge. 
 
Fig. 8. 
The effect of bilateral cervical vagotomy (Fig. 8A) and atropine (1 mg/kg i.v.) (Fig. 
8B) on the gastroprotective action of Ang II (191 pmol/rat i.c.v.). Each column represents 
mean ± S.E.M., the number of animals was 5 per group. **P<0.01; ***P<0.001 compared 
with the vehicle-treated group (column 1); 
##
P<0.01; 
###
P<0.001 compared with the agonist-
treated group (column 2); 
++
P<0.01 compared with vagotomized/atropine-treated group 
(column 3) (ANOVA, Newman-Keuls post hoc test). 
Highlights: 
 Ang II (i.c.v.) induces gastroprotection via a DAGL-dependent mechanism in rats. 
 Ang II (i.c.v.) fails to induce gastroprotection in CB1 (-/-) mice. 
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